"...getting closer to FDA approval..."??? Well, given that since the trial started 2-3 YEARS ago, they have done only 7-8 verifiable implants and MUST do 186-187 more PLUS one YEAR before even being CONSIDERED by the FDA, I'd say "closer to approval" is an extraordinarily optimistic way of describing it!
Just listen to see if they allow Rosa to speak. If yes, go SHORT! That's all you need to know -- Rosa speaks, go short IMMEDIATELY!
"...note holders chose to convert note to equity..."??? Perhaps they didn't have a choice. MNKD may have said, it's this or we file chapter 1,1 and since the SNY obligations are senior, they get pretty much everything if MNKD goes belly up. Given the choice between nothing or a new convert, I can see the logic.
"patient friendly solution"??? Beats a silly monstrosity that doesn't do ANYTHING except maybe give the aorta a "massage"!
"Future value, nobody knows..."??? Oh, I KNOW! Same value as right now -- ZERO!
I presume you mean JOSH Jennings:
"According to TipRanks..., Jennings is a 2-star analyst with an average return of 2.8% and a 50.0% success rate."
Wow! A TWO star analyst! And a 50% success rate to boot! Every bit as good as flipping a coin!! Woo-woo! I am soooooo impressed! He might have gotten a little better return than that whopping 2.8% if he hadn't been so STUPID as to recommend SSH!
Proboards? They should rename MNKD's forum there the "MNKDcircle-jerk" board...because that's all it really is, a bunch of idiots finding a million and one excuses for afrezza's and MKND's performance.
...no, what you "missed" were REAL patients tweeting about their success with lantus and humalog...you see, REAL diabetics DON't sit around day IN, day OUT, 27/7 tweeting OVER AND OVER how they're doing controlling the glucose or bragging about a1cs!
Diabetics, contrary to what everyone expected, simply aren't all that interested in afrezza. Also, obviously enough, docs aren't interested in afrezza. Despite all the claims about "social media" pushing afrezza, you can hardly find a single diabetic related forum, blog, or facebook page that mentions afrezza. And when something does show up, it's usually from "afrezzauser" or one of his "afrezza pump crew."
Toto, I don't think we're in Kansas anymore! A new ALL TIME LOW!!! For the US, at least! Of course, over in aussieland it traded down to PENNIES per share! Probably take a little while longer over here -- people aren't nearly as smart!
ACADEMIC cardiac surgeons are generally NOT "million dollar earners." They're usually weak kneed "whiz kid" Asperger types who complete their residency and suddenly have to face dealing with the REAL world, and they can't handle it. Hence, they get sucked back by the academic vaccum to where they can play scientist and pad their cvs and don't have to sweat annoying social interactions.
Funny how everyone seems able to "confirm" the ad, but the only photo available is of an ad RIPPED out of a diabetes magazine. It seems like it would have been just as simple to open Time to the ALLEGED afrezza ad, fold over the cover to reveal that it IS Time magazine and then snap a photo to post on ihub.
Given all the excitement it would generate, why doesn't someone do THAT?
As far as the Time ad, I've seen nothing but the ad ripped out of a diabetes magazine. Until I see it IN the magazine, I still say there is no Time ad for afrezza.
You hit the nail on the head! There are 30 MILLION diabetics, yet I defy you to name twenty who have posted about using afrezza. That DOESN'T include "afrezzauser" and his crew of promoters -- some of whom I'm confident aren't even diabetic.
After six months on the market, IF diabetics WERE interested, there would be HUNDREDS of blog comments, forum comments, etc , from HUNDREDs of different diabetics -- REAL diabetics. I couldn't even find a SINGLE facebook comment on ANY of the many diabetic related pages there.
Laura Kronen? Laura is a money hungary b_tch (google her lawsuit against her former employer) who is no doubt looking for ads -- at 250-500 bucks a month -- to support her blog that no one reads. Amy Tenderich also liked afrezza at first but then decided it wasn't working for her. Let me guess -- she sold out to big pharma! Am I right?
Mikep's thread? Man, do you really want to bring THAT up? After all, Mike had to give up afrezza after he developed a persistent cough caused BY afrezza. Not ot mention that of the 7-8 people you can find there that have tried afrezza, probably half quit using it for one reason or another. Did you notice that no one hasposted ANYTHING about afrezza in the past two weeks? Indeed, the last few posts on Mikep's thread were "empty" posts by "afrezzuser" crew meant only to "bump" the thread. before those, there hadn't been a post since mid-June!
"...the sales growth is also positive in raw terms..."??? Find another drug that has performed worse than afrezza in its first six months. You could sell arsenic laced tylenol faster than you could sell afrezza. Docs and diabetics simply aren't that interested in it.
As far as DTC, the ads I've seen have had more black boxes and warnings and caveats than anything promoting afrezza use. And who's idea was it to use that godawful scaggly old man? Why didn't they just use a photo of an afezza inhaler stuck into a pile of fresh dog manure -- would have been more appealing!
It seems to me that the primary short arguments should be:
1. Diabetics simply don't seem interested in afrezza. Even aside from script numbers, looking through various forums like tudiabetes, diabetes blogs, facebook, there is practically NO discussion of afrezza. Subtract the efforts of "afrezzauser" and his "crew" of half dozen or so and practically no one ever brings it up.
2. Afrezza sales are, in simple fact, pathetic, I doubt there has been a worse launch of a drug in the history of phramaceutical sales. Think the "Edsel" of drugs.
3. MNKD has "obligation" issues. First, it's obligated to repay 100 million bucks in a couple of weeks. Second, it's obligated to buy 150 million bucks -- give or take based on currency translation -- worth of insulin from a European pharma over the next few years. It's obligated to pay 90 million dollars to Deerfield as milestones are reached. There's the 50 million buck obligation to pay Mann Group.
Worst of all it's obligated to use the 175 million dollar "credit line" from SNY to pay its share of the losses on afrezza. The bad thing here is that the loan is secured by ALL of MNKD's assets -- afrezza, all of its insulin, even the Valencia facility. When Valencia is sold ALL of the dough must be used to repay the loan. ALL of MNKD's profits MUST be used to repay the loan. SNY has the option of ACCELERATING loan repayment under certain conditions, but I couldn't find what those are. Any refinancing of the 100 million will almost necessarily be a convert -- even more dilution -- or high interest junk bonds. Since there is no way of forecasting future losses, shareholders are left with their necks on the guillotine, so to speak.
The obvious counterargument are the milestone payments expected from SNY, but since no one knows the requirements to be met and since MNKD insists it can't reveal them -- something I find highly suspicious -- there's no way to anticipate whether they might salvage MNKD's future
Same thing as on ihub. Why were pages torn out? Can't identify anything to show it's actually in Time. The ad looks like the one from Diabetes Forecast. Smells a bit fishy I do believe.